10 recruiting, 5 active not recruiting, 4 completed, 3 terminated. 11 Phase 2, 9 Phase 1, 2 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow Hormone Receptor Positive Breast Carcinoma: new trials by email Literature Review of Hormone Receptor Positive Breast Carcinoma trials Research Report on Hormone Receptor Positive Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder Aromatase Inhibitors, Bupropion, GnRH agonist - Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Illinois at Chicago | 100 | 2026-09-01 | 2026-08-24 |
| Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia Tai Chi, Health Education - Hormone Receptor Positive Breast Carcinoma, Postmenopausal | Not applicable | Recruiting | Thomas Jefferson University | 40 | 2026-07-27 | 2026-08-14 |
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer ARX788, Computed Tomography (CT), Biospecimen Collection - HER2 Low Breast Carcinoma, Triple Negative Breast Cancer | Phase 2 | Recruiting | Laura Huppert, MD, BA | 36 | 2026-06-05 | 2026-06-11 |
| AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors AVA6103 - Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Avacta Life Sciences Ltd | 174 | 2026-03-31 | 2026-10-05 |
| Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype Trastuzumab deruxtecan (T-DXd, DS-8201a), CDK4/6i plus ET - Advanced Breast Cancer, Advanced Breast Carcinoma | Phase 2 | Recruiting | MedSIR | 200 | 2025-06-30 | 2026-07-30 |
| A Study of Revaree Plus in People With Breast Cancer Revaree Plus - Breast Cancer, Stage 0 Breast Cancer | Phase 4 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2025-06-20 | 2026-02-06 |
| DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients Biospecimen Collection - HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer | Recruiting | Mayo Clinic | 100 | 2024-04-30 | 2026-06-01 | |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors BGB-43395, Fulvestrant, Letrozole - Advanced Solid Tumor, Advanced Breast Cancer | Phase 1 | Recruiting | BeOne Medicines | 433 | 2023-12-01 | 2026-10-15 |
| Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study Palbociclib, Ribociclib, Abemaciclib - Breast Adenocarcinoma, Breast Cancer Stage IV | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 3500 | 2023-05-01 | 2025-02-03 | |
| CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer Breast Cancer, HER2-negative Breast Cancer | Unknown | Institut fuer Frauengesundheit | 3000 | 2023-03-10 | 2023-05-23 | |
| Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas IMT-009, Fruquintinib - Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Immunitas Therapeutics | 67 | 2022-11-28 | 2025-10-16 |
| Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma | Completed | University of Milano Bicocca | 254 | 2021-09-24 | 2025-07-25 | |
| Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer SM-88 - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Terminated | Georgetown University | 11 | 2021-09-22 | 2023-08-28 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Abexinostat Tosylate, Fulvestrant, Palbociclib - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Withdrawn | Pamela Munster | 2021-03-31 | 2021-05-18 | |
| Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy Educational Intervention, Text Message-based Navigation Intervention, Motivational Interviewing - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1167 | 2021-02-15 | 2026-10-19 |
| Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer Alpelisib, Fulvestrant, Aromatase inhibitor - Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer | Phase 2 | Active not recruiting | Marina N Sharifi | 44 | 2021-02-12 | 2026-01-02 |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) XL102, Fulvestrant, Abiraterone - Neoplasm Malignant, Epithelial Ovarian Cancer | Phase 1 | Terminated | Exelixis | 52 | 2021-02-10 | 2024-05-14 |
| Elacestrant in Preoperative Setting, a Window of Opportunity Study Elacestrant - Breast Cancer, Hormone Receptor Positive Breast Carcinoma | Early Phase 1 | Completed | SOLTI Breast Cancer Research Group | 23 | 2021-02-09 | 2022-10-26 |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan - Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 88 | 2020-10-09 | 2025-11-10 |
| Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 138 | 2020-09-15 | 2026-10-19 |
Showing 20 of 26. Sign in to see all of them.
Breast Neoplasms (16) · Triple Negative Breast Neoplasms (4) · Colorectal Neoplasms (3) · Neoplasm Metastasis (3) · Breast Diseases (2) · Neoplasms (2) · Breast Carcinoma In Situ (1) · Breast Neoplasms, Male (1) · Burkitt Lymphoma (1) · Carcinoma, Endometrioid (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1)
Neoplasms by Site (21) · Neoplasms (19) · Skin Diseases (19) · Skin and Connective Tissue Diseases (19) · Breast Diseases (17) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Colonic Diseases (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Intestinal Diseases (4) · Intestinal Neoplasms (4)
Fulvestrant (5) · abemaciclib (3) · Anastrozole (2) · Aromatase Inhibitors (2) · HMPL-013 (2) · Letrozole (2) · Specimen Handling (2) · elacestrant (2) · palbociclib (2) · trastuzumab deruxtecan (2) · ARX788 (1) · Alpelisib (1) · Amiloride (1) · Bupropion (1) · Early Intervention, Educational (1)
Exelixis (2) · Alliance for Clinical Trials in Oncology (1) · Avacta Life Sciences Ltd (1) · BeOne Medicines (1) · Centro di Riferimento Oncologico - Aviano (1) · City of Hope Medical Center (1) · ECOG-ACRIN Cancer Research Group (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Georgetown University (1) · Hutchison Medipharma Limited (1) · Immunitas Therapeutics (1) · Institut fuer Frauengesundheit (1) · Jonsson Comprehensive Cancer Center (1) · Laura Huppert, MD, BA (1) · Marina N Sharifi (1)
United States (19) · Italy (5) · Australia (3) · France (3) · Germany (3) · Spain (3) · Belgium (2) · Netherlands (2) · United Kingdom (2) · Austria (1) · Brazil (1) · China (1) · Czechia (1) · Ireland (1) · Japan (1)
Fabio Puglisi, MD (1) · Jennifer M Specht (1) · Joanne Mortimer, MD (1) · Katherine E. Reeder-Hayes, MD (1) · Kuang-Yi Wen, PhD (1) · Laura Huppert, MD (1) · Margaret Tonda (1) · Marina N Sharifi, MD (1) · Nadia Ashai, MD (1) · Nicholas P McAndrew, MD (1) · Oana Danciu, MD (1) · Pamela N Munster, MD (1) · Pooja Advani, MBBS, MD (1) · Ritesh Parajuli, MD (1) · Shari Goldfarb, MD (1)
PMID 36269154, PMID 37507802, PMID 37796398, PMID 37828596, PMID 40598566
2023 (1), P30CA033572 (1), R01CA237357 (1), U10CA180820 (1), UG1CA189823 (1)